Artiva Biotherapeutics
ARTV
53 hedge funds and large institutions have $62.8M invested in Artiva Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 7 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
1.24% less ownership
Funds ownership: 87.12% → 85.88% (-1.2%)
7% less funds holding
Funds holding: 57 → 53 (-4)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
71% less capital invested
Capital invested by funds: $213M → $62.8M (-$150M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.08M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$511K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$224K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$158K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$1.73M |
| 2 |
RI
RTW Investments
New York
|
-$1.5M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.04M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$418K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$302K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | +$286 | +53 | +40% |
|
52
Nisa Investment Advisors
St. Louis,
Missouri
| $492 | +$653 | +121 | +281% |
|
|
SCM
53
Sterling Capital Management
Charlotte,
North Carolina
| $474 | -$313 | -58 | -27% |
|
|
RI
54
RTW Investments
New York
| – | -$1.5M | -148,844 | Closed |
|
|
CAM
55
Cormorant Asset Management
Boston,
Massachusetts
| – | -$1.04M | -103,633 | Closed |
|
|
EC
56
EcoR1 Capital
San Francisco,
California
| – | -$418K | -41,453 | Closed |
|
|
57
Norges Bank
Oslo,
Norway
| – | -$302K | -30,000 | Closed |
|
|
MIM
58
MetLife Investment Management
Whippany,
New Jersey
| – | -$88K | -8,733 | Closed |
|
|
AWM
59
Avior Wealth Management
Omaha,
Nebraska
| – | -$2.26K | -224 | Closed |
|
|
GI
60
GAMMA Investing
Foster City,
California
| – | -$151 | -15 | Closed |
|
ARTV Hedge Fund Activity: Q1 2025 in Review
53 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q1 2025, worth a combined $62.8M — down 71% from $213M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ARTV and 3 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 23 added.
The largest buyer was BlackRock, adding an estimated $1.08M. The largest seller was venBio Partners, cutting an estimated $1.73M.
- 53 institutional investors held Artiva Biotherapeutics (ARTV) as of Q1 2025, down from 57 in Q4 2024.
- Funds reported $62.8M of Artiva Biotherapeutics stock for Q1 2025, down 71% quarter-over-quarter.
- 3 funds opened new Artiva Biotherapeutics positions in Q1 2025 and 7 closed out, a net change of -4 holders.
- The largest Artiva Biotherapeutics buyer in Q1 2025 was BlackRock, an estimated $1.08M added.
- The largest Artiva Biotherapeutics seller in Q1 2025 was venBio Partners, an estimated $1.73M sold.
Based on aggregated 13F filings for Q1 2025.